Acquisition Opportunity GBT is now part of Pfizer, suggesting potential alignment for integration of SCD therapies with Pfizer’s broader cardiovascular and rare disease portfolio. Explore co-promotion, distribution channels, and long-term collaboration on Oxbryta and related assets within Pfizer’s global footprint.

SCD Expansion Recent and ongoing work on sickle cell disease with Phase 3 trials and next-generation targets indicates continued R&D focus. Target partnerships for late-stage trials, real-world evidence studies, and expanded access programs in SCD to accelerate market adoption.

ESG and Access GBT launched an inaugural ESG report highlighting sustainable value and underserved patient communities. Leverage opportunities in payer negotiations, patient assistance programs, and value-based contracting to demonstrate social impact and improve formulary acceptance.

Global Trials International Phase 3 HOPE-KIDS 2 and broader trial activity imply a need for global clinical operations support. Offer CRO partnerships, site networks, and data management services to streamline multinational trial execution.

Technology Stack GBT’s tech stack includes cloud and digital governance tools (AWS, Google Cloud, Akamai, Tag Managers). Propose digital health or analytics collaborations, patient engagement platforms, and secure data integration for translational research and post-market surveillance.